World’s First Long-Term Colorectal Cancer Model by 3D Bioprinting as a Mechanism for Screening Oncolytic Viruses

Author:

McGuckin Colin1ORCID,Forraz Nico1ORCID,Milet Clément1ORCID,Lacroix Mathieu1ORCID,Sbirkov Yordan2ORCID,Sarafian Victoria2ORCID,Ebel Caroline3,Spindler Anita3,Koerper Véronique3,Balloul Jean-Marc3,Quéméneur Eric3ORCID,Zaupa Cécile3

Affiliation:

1. CTIPharma Department, Cell Therapy Research Institute, CTIBIOTECH, Bat A16, 5 Avenue Lionel Terray, Meyzieu, 69330 Lyon, France

2. Department of Medical Biology and Research Institute, Medical University of Plovdiv, 4002 Plovdiv, Bulgaria

3. Transgene, Illkirch-Graffenstaden, 67400 Strasbourg, France

Abstract

Long-term modelization of cancer as it changes in the human body is a difficult goal, particularly when designing and testing new therapeutic strategies. This becomes even more difficult with metastasis modeling to show chemotherapeutic molecule delivery directly to tumoral cells. Advanced therapeutics, including oncolytic viruses, antibody-based and cell-based therapies are increasing. The question is, are screening tests also evolving? Next-generation therapeutics need equally advanced screening tests, which whilst difficult to achieve, are the goal of our work here, creating models of micro- and macrotumors using 3D bioprinting. We developed advanced colorectal cancer tumor processing techniques to provide options for cellular expansion, microtumor printing, and long-term models, which allow for the evaluation of the kinetics of penetration testing, therapeutic success, targeted therapies, and personalized medicine. We describe how we tested tumors from a primary colorectal patient and, applying 3D bioprinting, matured long-term models for oncolytic metastatic screening. Three-dimensional microtumors were kept alive for the longest time ever recorded in vitro, allowing longitudinal studies, screening of oncolytic viruses and realistic modelization of colorectal cancer. These 3D bioprinted models were maintained for around 6 months and were able to demonstrate the effective delivery of a product to the tumoral environment and represent a step forward in therapeutic screening.

Funder

Fonds Unique Interministériel (FUI)—Banque Publique de l’Innovation (BPI) France, Metropoles of Lyon, and Grenoble, Lyonbiopole, Minalogic and La Région Auvergne-Rhône-Alpes

Auvergne-Rhône Alpes Region for its production platform of microtumors by 3D-bioprinting for cancer research

National Recovery and Resilience Plan of the Republic of Bulgaria

Publisher

MDPI AG

Subject

Cancer Research,Oncology

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3